홈

True Innovation for Ultimate health of Mankind
EXPLORE TIUMBIO

메리트

Happiness of mankind through the treatment
development of rare & incurable diseases
  • Market
    Target rare & incurable disease markets with high potential future growth
  • Pipeline
    High-value Pipeline that is distinctly competitive with a high success rate
  • Human
    Resource
    Researchers formed of topic experts with ample successful R&D experience
NCE401 (TU2218)
It is a small molecule antagonist to TGF-β signaling pathway, being developed as a treatment for cancer and fibrosis.

PIPELINE

See all news
NCE403 (TU2670)
It is a new GnRH antagonistic small molecule drug, being developed as a treatment for endometriosis.
NBP604 (TU7710)
It is a new biologics drug, being developed as a bypass factor treatment for neutralizing antibody-bearing hemophilia patients.
NBP611 (TU7918)
It is a new biologics drug, being developed as a treatment for type B hemophilia.

IR news

MORE

Investment Information

CEO.
Huntaek Kim
Address.
4F, 49, Daewangpangyo-ro 644beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, 13493, Republic of Korea
Business registration number.
291-87-00645
Tel.
070-4162-7320
Fax.
031-707-0919
Copyright © Tiumbio. Rights Reserved